# Kevin Kalinsky

Source: https://onco.cc/people/kevin-kalinsky/  
OnCo record `kevin-kalinsky` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led RxPONDER, which showed postmenopausal women with 1-3 positive nodes and low recurrence scores do not need chemotherapy.

## Summary

Kevin Kalinsky was principal investigator of SWOG S1007 (RxPONDER), which extended the TAILORx result to node-positive disease: postmenopausal women with one to three positive nodes and a recurrence score of 25 or less gained nothing from chemotherapy, while premenopausal women did. He directs breast oncology at Winship and leads SWOG breast trials on ctDNA-guided escalation.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: breast; de-escalation; swog
- Role: Director, Glenn Family Breast Center, Winship Cancer Institute of Emory University
- Specialisms: Breast cancer; Genomic assays; Node-positive disease; SWOG trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Kalinsky%20K%5BAuthor%5D%20RxPONDER

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [Oncotype DX](https://onco.cc/drugs/oncotype-dx/)
- institutions: [Winship Cancer Institute of Emory University](https://onco.cc/institutions/emory-winship/)
- trials: [RxPONDER (SWOG S1007)](https://onco.cc/trials/rxponder/)
- key papers: [Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer](https://onco.cc/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/)

---
JSON: https://onco.cc/api/v1/entities/kevin-kalinsky.json